Public–Private Partnership: Targeting Real-World Data for Hepatitis C Direct-Acting Antivirals-Reference-Cited by-同舟云学术

Public–Private Partnership: Targeting Real-World Data for Hepatitis C Direct-Acting Antivirals

Published:2017-09 Issue:3 Volume:153 Page:626-631
ISSN:0016-5085
Container-title:Gastroenterology
language:en
Short-container-title:Gastroenterology

Author:

Mishra Poonam,Florian Jeffry,Peter Joy,Vainorius Monika,Fried Michael W.,Nelson David R.,Birnkrant Debra

Funder

University of South Florida

Merck

University of North Carolina at Chapel Hill

National Center for Advancing Translational Sciences

GlaxoSmithKline

Bristol-Myers Squibb

Gilead Sciences

AbbVie

Janssen Pharmaceuticals

National Institutes of Health

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference26 articles.

1. Direct-acting antiviral drug approvals for treatment of chronic hepatitis C virus infection: scientific and regulatory approaches to clinical trial designs;Mishra;Hepatology,2015

2. Direct-acting antiviral drugs for the treatment of chronic hepatitis C virus infection: interferon free is now;Florian;Clin Pharmacol Ther,2015

3. HCV-TARGET. Hepatitis C Therapeutic Registry and Research Network. Available at: http://hcvtarget.org/index.php/2013/08/29/fda-news-release-aug-29-2013/. Accessed December 8, 2016.

4. Natural history of hepatitis C: its impact on clinical management;Di Biscegelie;Hepatology,2000

5. US Food and Drug Administration (FDA). Guidance for industry chronic hepatitis C virus infection: developing direct-acting antiviral drugs for treatment (draft May 2016). Available at: www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm225333.pdf. Accessed March 8, 2017.

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Outcomes of early vs late treatment initiation in solid organ transplantation from hepatitis C virus nucleic acid test-positive donors to hepatitis C virus-uninfected recipients: Results from the HCV-TARGET study;American Journal of Transplantation;2023-10

2. Prevalence of Immunomodulator Use as Combination Therapy With Vedolizumab or Ustekinumab in Inflammatory Bowel Disease;Clinical and Translational Gastroenterology;2023-07-14

3. Design and Rationale for a Real-World Observational Cohort of Patients Living with Progressive Neurological Disease and their care partners: TARGET-NEURO Study;2023-05-24

4. Leveraging Disease-Based Community Data to Provide Insights into Current Atopic Dermatitis Treatments;Recent Advances in the Treatment of Atopic Dermatitis [Working Title];2023-02-13

5. Long-term Follow-up of Hepatitis C Patients Who Achieved Sustained Virologic Response in the Pragmatic PRIORITIZE Study;Clinical Gastroenterology and Hepatology;2023-02